Will prothrombin complex concentrate replace plasma in cardiac surgical bleeding in North America?

Area of Science:

• Cardiology
• Hematology
• Anesthesiology

Background:

• Acquired coagulopathic bleeding is a significant concern in cardiac surgery.
• Plasma is the traditional treatment, but four-factor prothrombin complex concentrate (4F-PCC) is gaining interest.
• 4F-PCC has a different composition and potential advantages over plasma.

Purpose of the Study:

• To review the current evidence on the use of 4F-PCC for acquired coagulopathic bleeding in cardiac surgery.
• To compare the efficacy and safety of 4F-PCC with plasma.
• To summarize findings from recent clinical trials and mechanistic studies.

Main Methods:

• Review of current clinical evidence, including randomized controlled trials.
• Analysis of mechanistic data supporting 4F-PCC's role in hemostasis.
• Synthesis of findings from the FARES-II trial and other ongoing studies.

Main Results:

• 4F-PCC offers rapid reconstitution and a small administration volume, leading to increased use.
• Clinical trial evidence suggests 4F-PCC has superior hemostatic efficacy and safety compared to plasma.
• Mechanistic data support 4F-PCC's ability to normalize thrombin generation.

Conclusions:

• High-quality clinical evidence supports 4F-PCC for treating coagulopathic bleeding in cardiac surgery.
• Further research is needed on sex- and race-specific efficacy.
• Investigating the mechanism of reduced adverse events and use in under-represented procedures is ongoing.